Please wait while the formulary information is being retrieved.
AMITIZA (lubiprostone)
- chronic idiopathic constipation
- irritable bowel syndrome with constipation
- opiate pain medication causing severe constipation
24 mcg capsule
- 1 capsule (24 mcg) by oral route 2 times per day with food and water
8 mcg capsule
- 1 capsule (8 mcg) by oral route 2 times per day with food and water
Default screening record
- 1 capsule (8 mcg) by oral route 2 times per day with food and water
- 1 capsule (24 mcg) by oral route 2 times per day with food and water
- None
Contraindicated
- None
Severe
Moderate
- None
- Gastrointestinal obstruction
Contraindicated
- Severe diarrhea
Severe
Moderate
- None
AMITIZA (lubiprostone)
- chronic idiopathic constipation
- irritable bowel syndrome with constipation
- opiate pain medication causing severe constipation
- None
- Abdominal distension
- Acute abdominal pain
- Diarrhea
- Dizziness
- Flatulence
- Headache disorder
- Nausea
More Frequent
Severe
Less Severe
- Dyspnea
- Arthralgia
- Cough
- Depression
- Dyspepsia
- Fatigue
- Gastroesophageal reflux disease
- Influenza
- Loose stools
- Urinary tract infection
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Chest tightness
- Hypokalemia
- Hypotension
- Ischemic colitis
- Rectal bleeding
- Throat constriction
- Unconsciousness
Less Severe
- Anorexia
- Chest pain
- Constipation
- Cramps
- Dysgeusia
- Edema
- Eructation
- Fecal incontinence
- General weakness
- Hyperhidrosis
- Lethargy
- Malaise
- Muscle spasm
- Myalgia
- Palpitations
- Skin rash
- Symptoms of anxiety
- Syncope
- Tachycardia
- Tremor
- Weight gain
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Lubiprostone
Safety and effectiveness not established in pediatric patients; no efficacy established in trials for pediatric functional constipation.
- 1 Day – 18 Years
- Safety and effectiveness not established in pediatric patients; no efficacy established in trials for pediatric functional constipation.
Lubiprostone
- Severity Level:
2
- Additional Notes: Insuff human data avail; animal data sug dev tox
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Lubiprostone
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Chronic idiopathic constipation | |
| K59.04 | Chronic idiopathic constipation |
| Constipation predominant irritable bowel syndrome | |
| K58.1 | Irritable bowel syndrome with constipation |
| Opioid-induced constipation | |
| K59.09 | Other constipation |
| 0-9 | A-Z |
|---|---|
| K58.1 | Irritable bowel syndrome with constipation |
| K59.04 | Chronic idiopathic constipation |
| K59.09 | Other constipation |
Formulary Reference Tool